This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taubman, M. B. Search for Related Content PubMed PubMed Citation Articles by Taubman, M. B. Related Collections ACE/Angiotension receptors Cell signalling/signal transduction Functional genomics

(Circulation Research. 2003;92:9.)
© 2003 American Heart Association, Inc.

Editorials

Angiotensin II

A Vasoactive Hormone With Ever-Increasing Biological Roles

Mark B. Taubman

From the Zena and Michael A. Wiener Cardiovascular Institute and Department of Medicine, Mount Sinai School of Medicine, New York, NY.

Correspondence to Mark B. Taubman, Box 1269, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029. E-mail mark.taubman@mssm.edu

Key Words: angiotensin II • smooth muscle cells • arterial injury • gene array

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Angiotensin II (Ang II) is an octapeptide hormone that plays a central role in cardiovascular homeostasis. Typical of many proteins, Ang II was named on the basis of its first-demonstrated biological function—the ability to act as a vasoactive agonist and induce contraction of blood vessels. Over the years, Ang II has been shown to play important roles in mediating hypertension, heart failure, cardiac remodeling, diabetes, and the proliferative and inflammatory responses to arterial injury (see review¹). These findings have spawned the development of several classes of pharmacological agents designed at inhibiting the synthesis of Ang II (eg, angiotensin II-converting enzyme inhibitors) or blocking its action (eg, angiotensin II receptor antagonists). These agents are now widely used in the treatment of hypertension and congestive heart failure.

In conjunction with studies performed on animal models, there have been numerous studies examining the cellular effects of Ang II. Initial studies focused in particular on the role of Ang II as a contractile agonist and therefore on the signals induced by Ang II in vascular smooth muscle cells (SMCs) and cardiomyocytes associated with contraction, such as the mobilization of intracellular calcium ([Ca²⁺]_i) and the activation of protein kinase C (PKC). It was demonstrated that Ang II activated phospholipase C, resulting in the production of inositol trisphosphate (IP₃) and diacylglycerol, which in turn were responsible for the mobilization of [Ca²⁺]_i and the activation of PKC, respectively. Additional studies in SMC cultures examined the properties of Ang II as a growth . . . [Full Text of this Article]

This article has been cited by other articles:

				E. Mendez-Bolaina, J. Sanchez-Gonzalez, I. Ramirez-Sanchez, E. Ocharan-Hernandez, M. Nunez-Sanchez, E. Meaney-Mendiolea, A. Meaney, J. Asbun-Bojalil, A. Miliar-Garcia, I. Olivares-Corichi, et al. Effect of caveolin-1 scaffolding peptide and 17 -estradiol on intracellular Ca2+ kinetics evoked by angiotensin II in human vascular smooth muscle cells Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1953 - C1961. [Abstract] [Full Text] [PDF]